Pyrukynd

Chemical Namemitapivat
Dosage FormTablet (oral; 5 mg, 20 mg, 50 mg)
Drug ClassPruvate kinase activators
SystemMultiple
CompanyAgios Pharmaceuticals
Approval Year2022

Indication

  • For the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.
Document TitleYearSource
Pyrukynd (mitapivat) Prescribing Information. 2022Agios Pharmaceuticals, Inc., Cambridge, MA
Document TitleYearSource
Assessment report: Pyrukynd. 2022EMA
Drug updated on 5/31/2023

More on this drug: Clinical Trials